When to Reanalyze a Previously Negative Exome

A negative exome rarely means the answer isn’t there. It often means the answer isn’t knowable yet. Gene–disease knowledge advances quickly, and variants dismissed as uncertain today may become diagnostic tomorrow.

For clinicians, the practical question is timing. Reanalyzing raw exome data is a targeted, low-cost intervention that can convert an undiagnosed case into a definitive answer — most productively after enough new evidence has accumulated to change the interpretation.

Frequently asked questions

How often should a negative exome be reanalyzed?

A common interval is every 18–24 months. Because roughly 250 new gene–disease associations are published each year, waiting long enough for meaningful literature to accumulate improves the odds of a new diagnosis without repeating analysis prematurely.

What is the diagnostic yield of exome reanalysis?

Reanalysis of previously negative exomes produces new diagnoses in approximately 10–15% of cases. Yield depends on elapsed time, phenotype updates, and whether parental samples enable trio-based interpretation.

Does reanalysis require a new blood draw?

Usually not. Reanalysis reinterprets stored sequence data against current gene and variant knowledge. A new sample is needed only when expanding to parental trio testing or moving to genome sequencing.

What clinical events should prompt reanalysis?

New or evolving symptoms, a newly affected family member, availability of parental DNA, or simply significant time since the last analysis. Any of these can shift how a variant is classified.

Is reanalysis the same as re-sequencing?

No. Reanalysis reinterprets existing data. Re-sequencing generates new data, which is warranted only if coverage was poor or a broader test such as genome sequencing is being considered.

---

Why a negative exome is often provisional

Exome sequencing captures the protein-coding regions where most known pathogenic variants reside, but interpretation is bounded by current knowledge. When the first analysis is run, a causative variant may sit in a gene not yet linked to any disease, or in a gene whose phenotypic spectrum hasn’t yet expanded to match your patient.

Wenger and colleagues (2017) reported that clinical exome sequencing is nondiagnostic for about 75% of patients evaluated for a possible Mendelian disorder — the pool from which reanalysis draws its diagnoses.

The knowledge base moves fast. The same group estimated that roughly 250 gene–disease and 9,200 variant–disease associations are reported each year, and that supporting literature enabling a reanalysis diagnosis was typically only one to three years old. That gap between sequencing and discovery is exactly what reanalysis closes.

What the yield data show

Reanalysis is not a marginal exercise. Across independent cohorts it delivers a consistent incremental yield.

• In the systematic reanalysis by Wenger 2017, 4 of 40 previously nondiagnostic exomes (10%) reached a definitive diagnosis — each a de novo variant in a relevant autosomal-dominant disease gene.
• A 3-year follow-up cohort added 12 diagnoses among 46 undiagnosed individuals, raising yield from 41% to at least 53%.
• A broader review in neurodevelopmental disorders found that routine reanalysis increased total diagnostic yield by 10–15%.

Importantly, some gains require no new literature at all. Basel-Salmon and colleagues (2019) found that reevaluation by geneticists directly involved in a patient’s care produced a new definitive diagnosis in 11.9% of cases — using genes already known to be associated with the phenotype when the original report was issued. Fresh clinical eyes matter.

When to trigger reanalysis

No single rule fits every case. Use a combination of elapsed time and clinical change.

Time-based triggers

An 18–24 month interval balances the annual accrual of new gene–disease associations against the effort of reinterpretation. Because diagnostic literature at reanalysis is often just one to three years old, this window captures the most productive discoveries.

Phenotype-driven triggers

Rare disease phenotypes evolve. A child who presented with isolated developmental delay may later develop seizures, dysmorphism, or organ involvement. Each new Human Phenotype Ontology term sharpens variant filtering and can implicate a gene overlooked before.

Family-based triggers

A newly affected sibling, or the availability of parental samples for trio analysis, changes the interpretive math. Trio data resolves inheritance and flags de novo variants — the category that drove most diagnoses in the reanalysis cohorts above.

Reanalysis versus re-sequencing

These are distinct decisions. Reanalysis reinterprets stored sequence data against updated databases and classification criteria — no new sample, minimal cost. Re-sequencing or escalation to genome sequencing generates new data, and is appropriate when original coverage was inadequate, when structural or deep-intronic variants are suspected, or when the exome simply didn’t interrogate the region of interest.

For most previously negative exomes, reanalysis is the logical first step. It is faster, cheaper, and frequently sufficient.

If a patient’s exome was negative more than 18 months ago, or if their phenotype or family history has changed, raise reanalysis with a clinical geneticist or genetic counselor. The intervention is low-risk, but its timing and scope should be individualized. This article is educational and does not substitute for professional genetic evaluation.

---

3billion’s WES (Whole Exome Sequencing) includes reanalysis at no additional cost, carried out automatically without a separate request. If you need reanalysis of existing data, you can also reach out to us — click the button below to get started.